Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Core Insights - Enveric Biosciences, Inc. has entered into definitive agreements for the immediate exercise of certain outstanding series A and series B warrants [1] Company Summary - The company is focused on advancing next-generation neuroplastogenic small molecules aimed at addressing psychiatric and neurological disorders [1] - The agreements involve the purchase of up to an aggregate of 1,212,499 shares of common stock through series A warrants [1]